Proscia® Named to the 2019 CB Insights Digital Health 150 – List of Most Innovative Digital Health Startups

Proscia
By Author Proscia | October 2, 2019

Proscia recognized for achievements in advancing computational pathology to improve cancer research and diagnosis.

NEW YORK (PRWEB) OCTOBER 02, 2019

CB Insights today named Proscia to the inaugural Digital Health 150 ranking, showcasing the 150 most promising private digital health companies in the world. CB Insights CEO Anand Sanwal revealed the final Digital Health 150 during Future of Health, a gathering of top executives across some of the largest healthcare institutions, startups, and investment firms.

“From pharmaceuticals to patient care, technology is rapidly changing healthcare, and The Digital Health 150 showcases the 150 best startups spearheading innovation and change in the sector,” said CB Insights CEO Anand Sanwal. “It’s a privilege to use CB Insights’ data to identify and shine a light on these companies, and we look forward to tracking their success in 2019 and beyond.”

The Digital Health 150 companies span the globe, from Canada, China, Germany, Israel, the United States, and the United Kingdom, and are supported by more than 850 investors.

“Proscia is honored to be recognized as one of the most promising digital health companies. This is a reflection of our commitment to transforming cancer research and diagnosis by helping pathology go digital,” said David West, CEO of Proscia. “By making computational pathology a reality, Proscia is driving laboratory workflow efficiencies and unlocking new insights to improve patient outcomes.”

Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from hundreds of applications based on several factors including patent activity, investor quality, news sentiment analysis, proprietary Mosaic scores, market potential, partnerships, competitive landscape, team strength, and tech novelty. The Mosaic Score, based on CB Insights’ algorithm, measures the overall health and growth potential of private companies to help predict a company’s momentum.

Proscia has delivered against these metrics by transforming the 150-year-old manual and subjective practice of pathology with tools that go beyond the limits of the human mind. The company’s intelligent software and pipeline of deep learning applications augment what pathologists can see and do to accelerate research and elevate the standard of care. As the global cancer burden continues to rise, the practice of computational pathology that Proscia is advancing will be critical to keeping pace with the demand for diagnostic services and to uncovering the data required to fulfill the promise of precision care.

Quick facts on the 2019 Digital Health 150:

  • In 2018, these emerging private companies cumulatively raised $5.7B across 117 deals. They’re on track to surpass these numbers in 2019, with $3B raised across 73 deals as of Q2’19.
  • A total of 17 companies have reached a unicorn valuation of $1B or more. GRAIL, Oscar Health, and We Doctor round out the top three most funded companies on the list.
  • 116 of the Digital Health 150 are headquartered in the United States. Those based outside the United States include 17 from Asia, 16 from Europe, and 1 from Canada.
  • Over 850 unique investors have funded the Digital Health 150, with F-Prime Capital, New Enterprise Associates, and Google Ventures taking the top three spots as the most active investors.

About CB Insights
At CB Insights, we believe the most complex strategic business questions are best answered with facts. We are a machine intelligence company that synthesizes, analyzes and visualizes millions of documents to give our clients fast, fact-based insights. Serving the majority of the Fortune 100, we give companies the power to make better decisions, take control of their own future, and capitalize on change.

CB Insights Contact:
Hyeri Kim, Senior Manager – PR & Communications
[email protected]
+1 212-292-3148 ext. 3020

About Proscia
Proscia is a software company that is changing the way the world practices pathology to transform cancer research and diagnosis. With the company’s Concentriq™ digital pathology platform and pipeline of AI algorithms, laboratories are leveraging new kinds of data to improve patient outcomes and accelerate discoveries.* Proscia’s team of technologists, scientists, and pathologists is bringing a fresh approach to an outdated industry, helping the world to keep pace with the increasing demand for pathology services and fulfill the promise of precision care.

*Proscia’s products are for research use only.

Our website uses cookies. By using this site, you agree to its use of cookies.